Search results
Results from the WOW.Com Content Network
Forgoing medical care in favor of orthomolecular treatments can lead to adverse health outcomes. [6] Health professionals see orthomolecular medicine as encouraging individuals to dose themselves with large amounts of vitamins and other nutrients without conventional supervision, which they worry might be damaging to health.
Authoritative bodies such as the National Institute of Mental Health [12] and American Academy of Pediatrics [29] have criticized orthomolecular treatments as ineffective and toxic. A 1973 task force of the American Psychiatric Association charged with investigating orthomolecular claims concluded:
Main page; Contents; Current events; Random article; About Wikipedia; Contact us; Pages for logged out editors learn more
The Journal of Orthomolecular Medicine is not indexed by MEDLINE, a database of biomedical literature.Journals are selected for MEDLINE by the National Library of Medicine based on scope and coverage, quality of content, quality of editorial work, intended audience, quality of the layout, printing, graphics, and illustrations. [6]
In 1963, Ortho introduced the second oral contraceptive available in the United States (Ortho-Novum 10 and Ortho-Novum 2, produced by Syntex). In 1964, Ortho bought rights to and marketed the Gynekoil (Margulies Coil) and Lippes Loop inert plastic IUDs in the United States until the mid-1970s and 1985, respectively.
Phthalaldehyde (sometimes also o-phthalaldehyde or ortho-phthalaldehyde, OPA) is the chemical compound with the formula C 6 H 4 (CHO) 2. It is one of three isomers of benzene dicarbaldehyde, related to phthalic acid. This pale yellow solid is a building block in the synthesis of heterocyclic compounds and a reagent in the analysis of amino ...
Orthomol (full name: Orthomol pharmazeutische Vertriebs GmbH) is a family business based in Langenfeld, North Rhine-Westphalia, Germany. [3] It was founded by Kristian Glagau in 1991 and is now managed by his son Nils together with Michael Schmidt.
QuidelOrtho Corporation is an American manufacturer of diagnostic healthcare products that are sold worldwide. [3]On May 8, 2020 the U.S. Food and Drug Administration (FDA) issued to Quidel the first emergency use authorization (EUA) for a COVID-19 rapid antigen test, a new category of tests for use in the ongoing pandemic.